Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Sammy Saab. (2015) Evaluation of the impact of rehospitalization in the management of hepatic encephalopathy. International Journal of General Medicine 8, pages 165-173.
Read now
Read now
Nina Kimer, Aleksander Krag & Lise L Gluud. (2014) Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy. Patient Preference and Adherence 8, pages 331-338.
Read now
Read now
J Henrion & P Deltenre. (2013) DECOMPENSATED CIRRHOSIS … ARE WE GAINING GROUND?. Acta Clinica Belgica 68:6, pages 411-415.
Read now
Read now
Articles from other publishers (29)
Fateme Gorgani, Zahra Esfahani, Seyyed‐Hadi Ghamari, Erfan Ghasemi, Sina Azadnajafabad, Parnian Shobeiri, Esmaeil Mohammadi, Sahar Saeedi Moghaddam, Mohsen Abbasi‐Kangevari, Nima Fattahi, Yeganeh Sharifnejad Tehrani, Yosef Farzi, Negar Rezaei, Bagher Larijani & Farshad Farzadfar. (2022) Global, regional, and national burden and quality of care index of liver cirrhosis by cause from global burden of disease 1990–2019. Journal of Gastroenterology and Hepatology 38:1, pages 119-128.
Crossref
Crossref
Mai Abdel Moneim, Doaa H. Abdelaziz, Yosra Ibrahim Nagy, Amin Abdel Baki, Ahmed S. Attia & Nirmeen Sabry. (2021) Rifaximin microbial resistance and its efficacy and safety as a secondary prophylaxis of hepatic encephalopathy in patients with hepatitis C virus‐related cirrhosis. International Journal of Clinical Practice 75:11.
Crossref
Crossref
Christopher Ma, Alexander S. Qian, Nghia H. Nguyen, Igor Stukalin, Stephen E. Congly, Abdel Aziz Shaheen, Mark G. Swain, Anouar Teriaky, Sumeet K. Asrani & Siddharth Singh. (2021) Trends in the Economic Burden of Chronic Liver Diseases and Cirrhosis in the United States: 1996–2016. American Journal of Gastroenterology 116:10, pages 2060-2067.
Crossref
Crossref
V. N. Drozdov, E. V. Shikh, A. A. Astapovskiy, S. Yu. Serebrova & I. A. Komissarenko. (2021) Modern opportunities of pharmacological effect on gut microbiome and motor activity. Meditsinskiy sovet = Medical Council:12, pages 200-208.
Crossref
Crossref
Ching Chang, Chien-Hao Huang, Hsiao-Jung Tseng, Fang-Chen Yang & Rong-Nan Chien. (2021) Real-World Experience of the One-Year Efficacy of Rifaximin Add-On to Lactulose Is Superior to Lactulose Alone in Patients with Cirrhosis Complicated with Recurrent Hepatic Encephalopathy in Taiwan. Journal of Personalized Medicine 11:6, pages 478.
Crossref
Crossref
Piero Amodio & Sara Montagnese. (2021) Lights and Shadows in Hepatic Encephalopathy Diagnosis. Journal of Clinical Medicine 10:2, pages 341.
Crossref
Crossref
Robert E. Smith, Alice D. Friedman, James A. Murchison, S. Blake Tanner, P. Alexander Smith & Bradley T. Dollar. (2020) Acute Life-Threatening Complications of Portal Hypertension: a Review of Pathophysiology, Incidence, Management, and Cost. SN Comprehensive Clinical Medicine 2:9, pages 1628-1645.
Crossref
Crossref
Russell Rosenblatt, Johnathan Yeh & Paul J. Gaglio. (2020) Long-Term Management. Clinics in Liver Disease 24:2, pages 277-290.
Crossref
Crossref
Mohamed I. Elsaid, Tina John, You Li, Sri Ram Pentakota & Vinod K. Rustgi. (2020) The Health Care Burden of Hepatic Encephalopathy. Clinics in Liver Disease 24:2, pages 263-275.
Crossref
Crossref
Xavier Xiol Quingles, Sílvia Salord Vila, Alberto Amador Navarrete, Carme Baliellas Comellas, Alba Cachero Ros, Rosa Rota Roca, Valeria Pérez Campuzano & José Castellote Alonso. (2020) Quality of care provided to outpatients with hepatic cirrhosis in a teaching hospital. Revista Española de Enfermedades Digestivas.
Crossref
Crossref
Juan Miguel Abdo Francis, Mauricio de Ariño Suárez, Graciela Elia Castro Narro, René Malé Velázquez, Mayra Virginia Ramos Gómez, María Teresa Rizo Robles & José Antonio Velarde Ruiz Velasco. (2019) Encefalopatía hepática: historia natural de la enfermedad, nueva clasificación e impacto en la calidad de vida. Latin american journal of clinical sciences and medical technology 1:1, pages 50-58.
Crossref
Crossref
Mark Hudson & Marcus Schuchmann. (2019) Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence. European Journal of Gastroenterology & Hepatology 31:4, pages 434-450.
Crossref
Crossref
Donna M. Zucker & Rhoda Redulla. (2019) Lactulose Management of Minimal Hepatic Encephalopathy. Gastroenterology Nursing 42:1, pages 84-94.
Crossref
Crossref
Daniel Bodek, Pavan Patel, Sushil Ahlawat, Evan Orosz, Thayer Nasereddin & Nikolaos Pyrsopoulos. (2018) Superior Performance of Teaching and Transplant Hospitals in the Management of Hepatic Encephalopathy from 2007 to 2014. Journal of Clinical and Translational Hepatology 7:1, pages 1-10.
Crossref
Crossref
Aleksander Krag, Marcus Schuchmann, Hanna Sodatonou, Jeff Pilot, James Whitehouse, Simone I. Strasser & Mark Hudson. (2018) Design of the Prospective Real-world Outcomes Study of hepatic encephalopathy Patients’ Experience on Rifaximin-α (PROSPER): an observational study among 550 patients. Hepatology, Medicine and Policy 3:1.
Crossref
Crossref
Lindsay A Sobotka, Alice Hinton & Lanla F Conteh. (2018) Geographical differences exist in high-value care delivery for inpatient management of cirrhosis: Cost conscious care in cirrhosis. JGH Open 2:6, pages 276-281.
Crossref
Crossref
Kazuto TAJIRI, Yuka FUTSUKAICHI, Saito KOBAYASHI, Satoshi YASUMURA, Terumi TAKAHARA, Masami MINEMURA & Toshiro SUGIYAMA. (2018) L-Carnitine for the Treatment of Overt Hepatic Encephalopathy in Patients with Advanced Liver Cirrhosis. Journal of Nutritional Science and Vitaminology 64:5, pages 321-328.
Crossref
Crossref
Maria Garrido, Matteo Turco, Chiara Formentin, Michela Corrias, Michele De Rui, Sara Montagnese & Piero Amodio. (2017) An educational tool for the prophylaxis of hepatic encephalopathy. BMJ Open Gastroenterology 4:1, pages e000161.
Crossref
Crossref
Phunchai Charatcharoenwitthaya, Ngamphol Soonthornworasiri, Khemajira Karaketklang, Kittiyod Poovorawan, Wirichada Pan-ngum, Watcharasak Chotiyaputta, Tawesak Tanwandee & Kamthorn Phaosawasdi. (2017) Factors affecting mortality and resource use for hospitalized patients with cirrhosis. Medicine 96:32, pages e7782.
Crossref
Crossref
N Yu Stukova, Yu A Kucheryavyi, E A Mayevskaya & I V Maev. (2017) Ultrasound elastography of the liver for assessing the risk of complications of its cirrhosis of different etiologies. Terapevticheskii arkhiv 89:2, pages 38-44.
Crossref
Crossref
Duminda Suraweera, Vinay Sundaram & Sammy Saab. (2016) Evaluation and Management of Hepatic Encephalopathy: Current Status and Future Directions. Gut and Liver 10:4, pages 509-519.
Crossref
Crossref
Alesa Courson, G. Morgan Jones & Jennifer D. Twilla. (2015) Treatment of Acute Hepatic Encephalopathy. Journal of Pharmacy Practice 29:3, pages 212-217.
Crossref
Crossref
Jeffrey D. DellaVolpe, Jeffrey M. Garavaglia & David T. Huang. (2014) Management of Complications of End-Stage Liver Disease in the Intensive Care Unit. Journal of Intensive Care Medicine 31:2, pages 94-103.
Crossref
Crossref
Jennifer W. Harris & B. Mark Evers. 2015. Yamada' s Textbook of Gastroenterology. Yamada' s Textbook of Gastroenterology
2195
2210
.
Nina Kimer, Aleksander Krag, Flemming Bendtsen, Søren Møller & Lise Lotte Gluud. (2015) Rifaximin for people with hepatic encephalopathy. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Andy Liu. (2015) Advances in cirrhosis: Optimizing the management of hepatic encephalopathy. World Journal of Hepatology 7:29, pages 2871.
Crossref
Crossref
Jamile′ Wakim-Fleming, Mangesh R. Pagadala, Arthur J. McCullough, Rocio Lopez, Ana E. Bennett, David S. Barnes & William D. Carey. (2014) Prevalence of celiac disease in cirrhosis and outcome of cirrhosis on a gluten free diet: A prospective study. Journal of Hepatology 61:3, pages 558-563.
Crossref
Crossref
Liliane Lins & Jorge Bastos. (2014) Oral health protocol for liver transplant patients. Transplantation Technology 2:1, pages 2.
Crossref
Crossref
Doddy De Queljoe, Amelia Lorensia, Liana Widharta & Sugiarto Widjaja. (2013) Cost-Effectiveness Analysis of Pharmacotherapy for Hematemesis-Melena Treatment in Hospitalized Patients with Hepatic Cirrhosis. The Indonesian Biomedical Journal 5:1, pages 43.
Crossref
Crossref